Floatz logo

Immunoglobulin G4 [237-Proline,242-Proline,243-Valine,244-Alanine,De-245-Glycine], Anti-(Human Mucin-16) (Human Monoclonal Regn5668 ?4-Chain), Disulfide With Human Monoclonal Regn5668 ?-Chain, (235?228?),(238?231?)-Bis(Disulfide) With Immunoglobulin G4 [230-Proline,235-Proline,236-Valine,237-Alanine,De-238-Glycine,436-Arginine,437-Phenylalanine,446-Proline] Anti-(Human Cd28 Antigen) (Human Monoclonal Regn5668 ?4-Chain) Disulfide With Human Monoclonal Regn5668 ?-Chain

Ovarian Cancer

Explore 513 assets in Ovarian Cancer →
Floatz Rating
CC40/100
Confidence
Indicative
v0.2
Sponsor
Regeneron Pharmaceuticals
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT04590326CT.gov
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Ovarian Cancer

AssetSponsorPhaseRating
Immunoglobulin G4 [237-Proline,242-Proline,243-Valine,244-Alanine,De-245-Glycine], Anti-(Human Mucin-16) (Human Monoclonal Regn5668 ?4-Chain), Disulfide With Human Monoclonal Regn5668 ?-Chain, (235?228?),(238?231?)-Bis(Disulfide) With Immunoglobulin G4 [230-Proline,235-Proline,236-Valine,237-Alanine,De-238-Glycine,436-Arginine,437-Phenylalanine,446-Proline] Anti-(Human Cd28 Antigen) (Human Monoclonal Regn5668 ?4-Chain) Disulfide With Human Monoclonal Regn5668 ?-Chain (this asset)Regeneron PharmaceuticalsP1/2CC · 40
Tisotumab VedotinSeagen Inc.P2BB
TILInge Marie SvaneP2BB
OlaparibShandong UniversityP4BB
Cis-Diamminedichloroplatinum IiKalinski, Pawel, MD, PhDP3BB
AdriamycinGenmabP3BB
CarboplatinFudan UniversityP4BB
OTL-38On Target Laboratories, LLCP4BB
IrinotecanARCAGY/ GINECO GROUPP4BB

+42 more in the Ovarian Cancer cohort

Other indications for Immunoglobulin G4 [237-Proline,242-Proline,243-Valine,244-Alanine,De-245-Glycine], Anti-(Human Mucin-16) (Human Monoclonal Regn5668 ?4-Chain), Disulfide With Human Monoclonal Regn5668 ?-Chain, (235?228?),(238?231?)-Bis(Disulfide) With Immunoglobulin G4 [230-Proline,235-Proline,236-Valine,237-Alanine,De-238-Glycine,436-Arginine,437-Phenylalanine,446-Proline] Anti-(Human Cd28 Antigen) (Human Monoclonal Regn5668 ?4-Chain) Disulfide With Human Monoclonal Regn5668 ?-Chain

IndicationSponsorPhaseRating
Primary Peritoneal Carcinoma—P1/2CC · 43
Fallopian Tube Cancer—P1/2CC · 41
Endometrial Carcinoma—P1/2CC · 41

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G4 [237-Proline,242-Proline,243-Valine,244-Alanine,De-245-Glycine], Anti-(Human Mucin-16) (Human Monoclonal Regn5668 ?4-Chain), Disulfide With Human Monoclonal Regn5668 ?-Chain, (235?228?),(238?231?)-Bis(Disulfide) With Immunoglobulin G4 [230-Proline,235-Proline,236-Valine,237-Alanine,De-238-Glycine,436-Arginine,437-Phenylalanine,446-Proline] Anti-(Human Cd28 Antigen) (Human Monoclonal Regn5668 ?4-Chain) Disulfide With Human Monoclonal Regn5668 ?-Chain in Ovarian Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g4-237-proline242-proline243-valine244-alaninede-245-glycine-anti-human-mucin-16-human-monoclonal-regn5668-4-chain-disulfide-with-human-monoclonal-regn5668-chain-235228238231-bisdisulfide-with-immunoglobulin-g4-230-proline235-proline236-valine237-alaninede-238-glycine436-arginine437-phenylalanine446-proline-anti-human-cd28-antigen-human-monoclonal-regn5668-4-chain-disulfide-with-human-monoclonal-regn5668-chain-ovarian-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →